Yuji Omiya

Dr. Yuji Omiya


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YOYuji Omiya
Yuji Omiya
MYMitsutoshi Yuzurihara
Mitsutoshi Yuzurihara
YSYasuyuki Suzuki
Yasuyuki Suzuki
YKYoshio Kase
Yoshio Kase
TKToru Kono
Toru Kono

1 January 2005 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
YOYuji Omiya
Yuji Omiya
YSYasuyuki Suzuki
Yasuyuki Suzuki
MYMitsutoshi Yuzurihara
Mitsutoshi Yuzurihara
MMMikio Murata
Mikio Murata
MAMasaki Aburada
Masaki Aburada
STShuichi Takeda
Shuichi Takeda
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

18 March 2015 in Journal of Natural Medicines
Verified
Journal Article
Open access
PDF file
NKNoriko Kaifuchi
Noriko Kaifuchi
YOYuji Omiya
Yuji Omiya
HKHirotaka Kushida
Hirotaka Kushida
MFMiwako Fukutake
Miwako Fukutake
HNHiroaki Nishimura
Hiroaki Nishimura
YKYoshio Kase
Yoshio Kase
Shakuyakukanzoto (SKT) is a kampo medicine composed of equal proportions of Glycyrrhizae radix (G. radix) and Paeoniae radix (P. radix). A double-blind study reported that SKT significantly ameliorated painful muscle cramp in cirrhosis patients without the typical severe side effects of muscle weakness and central nervous system (CNS) depression. Previous basic studies reported that SKT and its active components induced relaxation by a direct action on skeletal muscle and that SKT did not depress CNS functions; however, why SKT has a lower incidence of muscle weakness remains unknown. In the present study, we investigated which components are absorbed into the blood of rats after a single oral administration of SKT to identify the active components of SKT. We also investigated the effects of SKT and its components on the twitch contraction induced by physiological Ca2+ release. Our study demonstrated that SKT and five G. radix isolates, which are responsible for the antispasmodic effect of SKT, did not inhibit the twitch contraction in contrast to dantrolene sodium, a direct-acting peripheral muscle relaxant, indicating that the mechanisms of muscle contraction of SKT and dantrolene in skeletal muscle differ. These findings suggest that SKT does not reduce the contractile force in skeletal muscle under physiological conditions, i.e., SKT may have a low risk of causing muscle weakness in clinical use. Considering that most muscle relaxants and anticonvulsants cause various harmful side effects such as weakness and CNS depression, SKT appears to have a benign safety profile.

6 January 2021 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
YMYuichi Miyamura
Yuichi Miyamura
HSHitomi suzuro
Hitomi suzuro
YOYuji Omiya
Yuji Omiya
IUIzumi Ujihara
Izumi Ujihara
SKShoichiro Kokabu
Shoichiro Kokabu
KOKentaro Ono
Kentaro Ono

Verified
Journal Article
Open access
PDF file
SOShotaro Otsuka
Shotaro Otsuka
KFKeita Fukumaru
Keita Fukumaru
ATAkira Tani
Akira Tani
STSeiya Takada
Seiya Takada
Kiyoshi KikuchiKiyoshi Kikuchi
Kiyoshi Kikuchi
IMIkuro Maruyama
Ikuro Maruyama
Physical frailty is an aging-related clinical syndrome involving decreases in body weight, mobility, activity, and walking speed that occurs in individuals with sarcopenia and is accelerated by increased oxidative stress. Ninjin’yoeito, a traditional Japanese Kampo medicine, is used for treating conditions, including anemia and physical weakness. Here, we investigated whether ninjin’yoeito could improve physical frailty by controlling oxidative stress in the senescence-accelerated mouse prone 8 (SAMP8) model. First, SAMP8 mice were divided into two groups, ninjin’yoeito treated and untreated, with the former consuming a diet containing 3% ninjin’yoeito from 3 months of age. At 7 months of age, body weight, motor function, locomotor activity, and mean walking speed were measured. Subsequently, mice were euthanized and measured for muscle weight, 8-hydroxy-2′-deoxyguanosine levels in muscle and brain, and cleaved caspase-3 expression in brain. The results showed reductions in weight, locomotor function, locomotion, and average walking speed in the untreated group, which were significantly improved by ninjin’yoeito. Furthermore, 8-hydroxy-2′-deoxyguanosine levels were reduced in muscle and brain from ninjin’yoeito-treated mice, compared with the levels in untreated mice; cleaved caspase-3 expression was similarly reduced in brain from the treated mice, indicating reduced apoptosis. Our findings suggest that ninjin’yoeito inhibits sarcopenia-based physical frailty through its antioxidant effects.

27 May 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
ZKZenji Kawakami
Zenji Kawakami
YOYuji Omiya
Yuji Omiya
KMKazushige Mizoguchi
Kazushige Mizoguchi
The traditional Japanese Kampo medicine yokukansan (YKS) is effective for behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s disease. As the pharmacological mechanisms, YKS is known to protect astrocytes from thiamine-deficiency (TD)-induced decreased glutamate (Glu) uptake and neuron model cells (PC 12 cells) from Glu-induced death. Yokukansankachimpihange (YKSCH) is an alternative formula to YKS, in which Citrus unshiu peel and Pinellia tuber are added to the YKS components, and is sometimes used to treat BPSD, but its pharmacological properties remain unknown. This study aims to investigate the cellular pharmacological effects of YKS and YKSCH on glutamatergic pathways, compare their efficacy, and determine the differences and similarities in the activities between these formulations. First, we examined the effects of YKS and YKSCH on Glu uptake by cultured astrocytes under TD conditions. We observed significant ameliorative effects of YKS and YKSCH on the TD-induced decrease in Glu uptake, with a 50% effective dose of 8.9 ± 1.8 μg/mL and 45.3 ± 9.2 μg/mL, respectively. Second, using cultured PC12 cells as a model for neurons, we examined the effects of YKS and YKSCH on Glu-induced cell death. We observed that YKS and YKSCH had significant inhibitory effects on Glu-induced cell death, with a 30% effective dose of 51.4 ± 20.8 μg/mL and 49.2 ± 11.0 μg/mL, respectively. Thus, while YKSCH was less effective than YKS in ameliorating the TD-induced decrease in Glu uptake by astrocytes, the two drugs showed similar inhibitory effects on Glu-induced PC12 cell death. These findings are important for understanding the differences and similarities in pharmacological actions between these drugs.